Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» bispecific antibodies
bispecific antibodies
Following bispecific deal with Pfizer, quiet California biotech raises $65M, heads to the clinic
Endpoints
Tue, 06/14/22 - 07:25 pm
Dren Bio
Pfizer
bispecific antibodies
ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma
Pharmaforum
Mon, 06/6/22 - 09:52 am
JNJ
Pfizer
ASCO 2022
bispecific antibodies
relapsed or refractory multiple myeloma
Roche trumpets new glofitamab data in lymphoma at ASCO
Pharmaforum
Fri, 05/27/22 - 10:24 am
Roche
ASCO 2022
glofitamab
lymphoma
bispecific antibodies
Cancer biotech Rondo gets $67M to step on the gas with next-gen bispecific drugs
MedCity News
Fri, 03/4/22 - 09:38 am
Rondo Therapeutics
bispecific antibodies
solid tumors
cancer
funding
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Sun, 01/30/22 - 11:53 am
Roche
FDA
bispecific antibodies
Regeneron
Vabysmo
wet age-related macular degeneration
diabetic macular edema
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies
BioSpace
Tue, 01/11/22 - 11:32 am
Pfizer
Dren Bio
R&D
bispecific antibodies
J&J goes after another FDA approval for a cancer bispecific
Pharmaforum
Thu, 12/30/21 - 10:53 am
JNJ
bispecific antibodies
cancer
FDA
Janssen
teclistamab
Multiple Myeloma
ASH: Roche uncorks eyepopping responses in bispecific test, hoping to add a jewel to its future portfolio
Endpoints
Sun, 12/12/21 - 11:31 pm
ASH2021
Roche
Genentech
bispecific antibodies
blood cancer
mosunetuzumab
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
Fierce Biotech
Mon, 10/4/21 - 11:08 am
JNJ
Xencor
biobucks
Roche
Regeneron
bispecific antibodies
blood cancers
plamotamab
FDA starts review of Roche’s eye disease drug, setting up 2022 verdict
Pharmaforum
Thu, 07/29/21 - 10:57 pm
Roche
faricimab
bispecific antibodies
diabetic macular edema
wet age-related macular degeneration
Hemab raises $55M to target multiple rare bleeding indications
Fierce Biotech
Thu, 07/22/21 - 10:55 am
Hemab
funding
monoclonal antibodies
bispecific antibodies
Roche takes the Tim-3 battle to Novartis
EP Vantage
Thu, 07/22/21 - 10:53 am
Roche
sabatolimab
Novartis
RG7769
bispecific antibodies
J&J, Vor ally to assess bispecific and stem cell therapy in AML
Fierce Biotech
Fri, 07/9/21 - 10:13 am
JNJ
Vor Biopharma
bispecific antibodies
stem cell therapy
AML
AbbVie jumps on the BCMA train, opting into TeneoOne buy
Pharmaforum
Thu, 06/24/21 - 12:29 pm
AbbVie
TeneoOne
M&A
bispecific antibodies
BCMA
Compass inks Trigr takeover to land clinical-phase bispecific
Fierce Biotech
Fri, 05/14/21 - 11:04 am
Compass Therapeutics
bispecific antibodies
M&A
Trigr Therapeutics
solid tumors
Merck KGaA lands rights to 3rd F-star oncology bispecific antibody
Fierce Biotech
Fri, 04/2/21 - 10:46 am
Merck KGaA
F-star Therapeutics
immuno-oncology
bispecific antibodies
Roche's bispecific matches Regeneron's Eylea in phase 3 trials
Fierce Biotech
Mon, 12/21/20 - 11:02 am
Roche
faricimab
diabetic macular edema
clinical trials
Regeneron
Eylea
bispecific antibodies
J&J taps the bispecific experts at Xencor for prostate cancer discovery pact, kicking off with $50M upfront
Endpoints
Mon, 12/7/20 - 10:45 am
JNJ
Xencor
Janssen
bispecific antibodies
prostate cancer
AbCellera acquires OrthoMab bispecific platform from Dualogics
Pharmaceutical Business Review
Fri, 08/21/20 - 12:01 pm
AbCellera
OrthoMab
bispecific antibodies
Dualogics
Amgen tosses back unwanted bispecific to Xencor as KRAS data on track for 2020 readout
Fierce Biotech
Wed, 07/29/20 - 12:04 pm
Amgen
bispecific antibodies
Xencor
Pages
« first
‹ previous
1
2
3
4
next ›
last »